Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income towards Parent Company of -$293000.0 for Q1 2026, up 97.13% year-over-year from -$148636.3 in Q1 2025, and up 98.13% quarter-over-quarter from -$15.7 million in Q4 2025.
Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$293000.0 for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 97.13% year-over-year to -$293000.0; the TTM figure through Mar 2026 stood at -$21.1 million (changed 0.31% YoY), while the FY2025 annual figure was -$26.2 million, down 152.45% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$293000.0, up from -$15.7 million in the prior quarter.
- The five-year high for Income towards Parent Company was $21.4 million in Q1 2022, with the low at -$8.0 billion in Q4 2023.
- The 5-year median for Income towards Parent Company is -$7.9 million (2023), against an average of -$480.3 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company tumbled 9157.22% in 2023, then surged 106.25% in 2024.
- Curaleaf Holdings' Income towards Parent Company stood at -$86.4 million in 2022, then sank by 9157.22% to -$8.0 billion in 2023, then surged by 99.86% to -$11.3 million in 2024, then tumbled by 38.46% to -$15.7 million in 2025, then soared by 98.13% to -$293000.0 in 2026.
- Business Quant data shows CURLF's Income towards Parent Company at -$293000.0 in Q1 2026, -$15.7 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31,000.00 |
| Mar 31, 2026 | -293,000.00 |
| Dec 31, 2025 | -15.66 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Mar 31, 2025 | -10.19 Mn |
| Dec 31, 2024 | -11.31 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | 567,000.00 |
| Dec 31, 2023 | -8.00 Bn |
| Sep 30, 2023 | -25.92 Mn |
| Jun 30, 2023 | -7.90 Mn |
| Mar 31, 2023 | -12.59 Mn |
| Dec 31, 2022 | -86.37 Mn |
| Sep 30, 2022 | -12.73 Mn |
| Jun 30, 2022 | -4.50 Mn |
| Mar 31, 2022 | 21.39 Mn |
| Dec 31, 2021 | -5.24 Mn |
| Sep 30, 2021 | 63.74 Mn |